ATE247652T1 - 4-substituierte chinolinderivate als nk-3 und/oder gaba(a) rezeptor liganden - Google Patents

4-substituierte chinolinderivate als nk-3 und/oder gaba(a) rezeptor liganden

Info

Publication number
ATE247652T1
ATE247652T1 AT00919753T AT00919753T ATE247652T1 AT E247652 T1 ATE247652 T1 AT E247652T1 AT 00919753 T AT00919753 T AT 00919753T AT 00919753 T AT00919753 T AT 00919753T AT E247652 T1 ATE247652 T1 AT E247652T1
Authority
AT
Austria
Prior art keywords
compounds
gaba
receptors
receptor ligands
quinoline derivatives
Prior art date
Application number
AT00919753T
Other languages
English (en)
Inventor
Jun Yuan
George D Maynard
Alan Hutchison
Stanislaw Rachwal
Original Assignee
Neurogen Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurogen Corp filed Critical Neurogen Corp
Application granted granted Critical
Publication of ATE247652T1 publication Critical patent/ATE247652T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G01N33/9406—Neurotransmitters
    • G01N33/9426—GABA, i.e. gamma-amino-butyrate
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70571—Assays involving receptors, cell surface antigens or cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Addiction (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AT00919753T 1999-03-29 2000-03-28 4-substituierte chinolinderivate als nk-3 und/oder gaba(a) rezeptor liganden ATE247652T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12692699P 1999-03-29 1999-03-29
PCT/US2000/008205 WO2000058303A1 (en) 1999-03-29 2000-03-28 4-substituted quinoline derivatives as nk-3 and/or gaba(a) receptor ligands

Publications (1)

Publication Number Publication Date
ATE247652T1 true ATE247652T1 (de) 2003-09-15

Family

ID=22427414

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00919753T ATE247652T1 (de) 1999-03-29 2000-03-28 4-substituierte chinolinderivate als nk-3 und/oder gaba(a) rezeptor liganden

Country Status (8)

Country Link
US (2) US6413982B1 (de)
EP (1) EP1165542B1 (de)
JP (1) JP2002540203A (de)
AT (1) ATE247652T1 (de)
AU (2) AU4038600A (de)
CA (1) CA2368455A1 (de)
DE (1) DE60004654T2 (de)
WO (2) WO2000058313A1 (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000058313A1 (en) 1999-03-29 2000-10-05 Neurogen Corporation 4-substituted quinoline derivatives as gaba receptor ligands
AU1481701A (en) * 1999-11-12 2001-06-06 Neurogen Corporation Bicyclic and tricyclic heteroaromatic compounds
GB0117396D0 (en) 2001-07-17 2001-09-05 Glaxo Group Ltd Chemical compounds
DK1497266T3 (da) 2002-03-27 2008-10-06 Glaxo Group Ltd Quinolinderivater og deres anvendelse som 5HT6-ligander
GB0226462D0 (en) * 2002-11-13 2002-12-18 Merck Sharp & Dohme Therapeutic agents
GB0308208D0 (en) 2003-04-09 2003-05-14 Glaxo Group Ltd Chemical compounds
TW200523253A (en) 2003-07-22 2005-07-16 Arena Pharm Inc Diaryl and arylheteroaryl urea derivatives as modulators of the 5-ht2a serotonin receptor useful for the prophylaxis and treatment of disorders related thereto
WO2005061462A2 (en) * 2003-12-19 2005-07-07 Neurogen Corporation Diaryl pyrazole derivatives and their use as neurokinin-3 receptor modulators
WO2005066137A1 (en) * 2003-12-19 2005-07-21 Neurogen Corporation 2,5-diaryl-1h-imidazole-4-carboxamides as neurokinin-3 receptor modulators for the treatment of central nervous system and peripheral diseases
US20050277639A1 (en) * 2004-03-02 2005-12-15 Phil Skolnick 2-Pyridinyl[7-(substituted-pyridin-4-yl)pyrazolo[1,5-a]pyrimidin-3-yl]methanones
US7879909B2 (en) 2004-04-12 2011-02-01 United Therapeutics Corporation Use of Treprostinil to treat neuropathic diabetic foot ulcers
MXPA06013414A (es) * 2004-05-18 2007-01-23 Schering Corp 2-quinolil-oxazoles sustituidos utiles como inhibidores de fosfodiesterasa 4.
AU2008264999B8 (en) * 2007-06-18 2013-10-31 Richter Gedeon Nyrt. Sulfonyl-quinoline derivatives
US9084742B2 (en) 2007-12-12 2015-07-21 Axovant Sciences Ltd. Combinations comprising 3-phenylsulfonyl-8-piperazinyl-1yl-Quinoline
US7863295B2 (en) * 2008-02-12 2011-01-04 Children's Medical Center Corporation Treatments for neuropathy
WO2009123714A2 (en) 2008-04-02 2009-10-08 Arena Pharmaceuticals, Inc. Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor
WO2010062321A1 (en) 2008-10-28 2010-06-03 Arena Pharmaceuticals, Inc. Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2h-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)-urea and crystalline forms related thereto
JP2018516992A (ja) 2015-06-12 2018-06-28 アクソファント サイエンシーズ ゲーエムベーハーＡｘｏｖａｎｔ Ｓｃｉｅｎｃｅｓ Ｇｍｂｈ レム睡眠行動障害の予防および処置のために有用なジアリールおよびアリールヘテロアリール尿素誘導体
AU2016291673A1 (en) 2015-07-15 2018-01-25 Axovant Sciences Gmbh Diaryl and arylheteroaryl urea derivatives for the prophylaxis and treatment of hallucinations associated with a neurodegenerative disease

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5484944A (en) * 1993-10-27 1996-01-16 Neurogen Corporation Certain fused pyrrolecarboxanilides and their use as GABA brain receptor ligands
PL186075B1 (pl) 1994-05-27 2003-10-31 Smithkline Beechem Spa N-(-etylobenzylo)-3-hydroksy-2-fenylochinolino-4-karboksyamid oraz kompozycja farmaceutyczna zawierająca ten związek
IT1270615B (it) * 1994-07-14 1997-05-07 Smithkline Beecham Farma Uso di derivati di chinolina
WO1996020193A1 (en) 1994-12-23 1996-07-04 Smithkline Beecham Corporation Compounds and methods
GB9524137D0 (en) 1995-11-24 1996-01-24 Smithkline Beecham Spa Novel compounds
GB9524104D0 (en) 1995-11-24 1996-01-24 Smithkline Beecham Spa Novel compounds
AR004735A1 (es) 1995-11-24 1999-03-10 Smithkline Beecham Spa Quinoleina 4-amido sustituida, un procedimiento para su preparacion, una composicion farmaceutica que los contiene y el uso de los mismos para lapreparacion de un medicamento.
BR9611820A (pt) 1995-11-24 1999-07-13 Smithkline Beecham Spa Derivados de quinolina
US5792766A (en) 1996-03-13 1998-08-11 Neurogen Corporation Imidazo 1,5-c! quinazolines; a new class of GABA brain receptor ligands
JP2002500645A (ja) 1997-05-23 2002-01-08 スミスクライン・ビーチャム・ソシエタ・ペル・アチオニ Ｎｋ−２およびｎｋ−３レセプターアンタゴニストとしてのキノリン−４−カルボキシアミド誘導体
AP1201A (en) 1997-09-17 2003-09-01 Smithkline Beecham Corp Method for the synthesis of quinoline derivatives.
US6228868B1 (en) * 1998-07-27 2001-05-08 Abbott Laboratories Oxazoline antiproliferative agents
WO2000058313A1 (en) 1999-03-29 2000-10-05 Neurogen Corporation 4-substituted quinoline derivatives as gaba receptor ligands

Also Published As

Publication number Publication date
WO2000058303A9 (en) 2002-12-19
US6624175B2 (en) 2003-09-23
EP1165542A1 (de) 2002-01-02
US20020198232A1 (en) 2002-12-26
JP2002540203A (ja) 2002-11-26
US6413982B1 (en) 2002-07-02
AU4038600A (en) 2000-10-16
CA2368455A1 (en) 2000-10-05
DE60004654D1 (de) 2003-09-25
WO2000058303A1 (en) 2000-10-05
DE60004654T2 (de) 2004-06-24
WO2000058313A1 (en) 2000-10-05
AU4038000A (en) 2000-10-16
EP1165542B1 (de) 2003-08-20

Similar Documents

Publication Publication Date Title
ATE247652T1 (de) 4-substituierte chinolinderivate als nk-3 und/oder gaba(a) rezeptor liganden
YU51703A (sh) Derivati benzimidazola i piridilimidazola kao veznici za gaba receptore
DE60231341D1 (de) Fluor- und sulfonylaminohaltige, 3,6-disubstituierptorantagonisten
BRPI0418112A (pt) inibidores de p-38 quinase bicìclico heterocìclicos
ATE347553T1 (de) Amino-substituierte pyrazolo 1,5-aö-1,5- pyrimidine und pyrazolo 1,5-aö-1,3,5-triazine
NO20070347L (no) Modulatorer av alfa7 nikotinske acetylkolinreseptorer og terapeutiske anvendelser
MXPA04000372A (es) Compuesto biciclicos de heteroarilo fusionados sustituidos con heteroarilo como ligandos del receptor gabaa.
ATE293448T1 (de) Benzo(d)azepin-derivative als 5-ht6-rezeptor- antagonisten
MA29140B1 (fr) Dérivés de quinoléine hétéroaromatiques et leur utilisation comme inhibiteurs de PDE10
HK1098460A1 (en) Fused hetrocyclic compounds and their use as metabotropic receptor antagonists for the treatment of gastrointestinal disorders
ATE342253T1 (de) Azabicycloderivate als antagonisten des muscarinischen rezeptors
MA31521B1 (fr) Dérivés de 2,3-dihydrobenzo[1,4] dioxin-2-ylméthyle utilisés en tant qu'antagonistes des alpha2c pour traiter des maladies des systèmes nerveux périphérique et central
MA30539B1 (fr) Derives de piperazinyle utiles dans le traitement de maladies induites par le recepteur gpr38.
DE60206198T2 (de) Tetrahydrochinolinderivate als muscarinische agonisten
TW200624432A (en) Imidazo [1,2-a] pyridine compounds, compositions, uses and methods related thereto
NO306779B1 (no) Naftalamider, anvendelse derav og farmasöytisk preparat
ATE428694T1 (de) N-ä1h-indol-5-ylünaphthalin-1-sulphonamid- derivate und verwandte verbindungen als serotonin 5-ht6 rezeptor antagonisten zur behandlung von erkrankungen des zentralen nervensystems
DE60309852D1 (de) Chinolin- und aza-indolderivate und deren verwendung als 5-ht6 liganden
EA200501593A1 (ru) Азабициклические производные в качестве антагонистов мускаринового рецептора
HUP0202534A2 (hu) Kondenzált pirrolkarboxamidok és a vegyületeket tartalmazó gyógyászati készítmények
ATE429421T1 (de) Arylindenopyridin- und arylindenopyrimidinverbindungen und ihre verwendung als adenosin-a2a-rezeptor antagonisten
DE60313898D1 (de) Substituierte azabicyclo hexane derivate als muscarin rezeptor antagonisten
MA29694B1 (fr) Derives de l'imidazopyridine comme ligands du recepteur cannabinoide
MXPA04000023A (es) Derivados de acido cicloalquilpirrol-3-carboxilico y derivados de acido heterocicloalquilpirrol-3-carboxilico como ligandos de receptor gabaa.
ATE386519T1 (de) Benzimidazole derivate und ihre anwendung als gaba a rezeptor komplex modulatoren

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1165542

Country of ref document: EP

REN Ceased due to non-payment of the annual fee